Achieve Life Sciences Cash Flow Statement
NASDAQ: QUITHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
5.56-0.31 (-5.28%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Achieve Life Sciences free cash flow
In fiscal 2025, Achieve Life Sciences generated -$49.5 million of operating cash flow and spent $3,000 on capital expenditures. That left free cash flow of -$49.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Achieve Life Sciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -54.65M | -39.83M | -29.82M | -42.35M | -33.15M | -14.73M | -16.39M | -12.69M | -10.58M | -1.23M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 228.00K | 229.00K | 228.00K | 236.00K | 250.00K | 255.00K | 31.00K | 60.00K | 59.00K | 188.00K |
| Stock-Based Compensation | 8.76M | 5.33M | 3.44M | 3.27M | 2.19M | 1.29M | 1.20M | 854.00K | 348.00K | 1.65M |
| Change in Working Capital | — | 567.00K | 134.00K | -132.00K | 281.00K | -979.00K | 908.00K | -86.00K | -363.00K | -12.04M |
| Operating Cash Flow | -49.47M | -29.77M | -24.48M | -37.57M | -29.44M | -13.47M | -15.22M | -10.62M | -9.11M | -202.00K |
| Capital Expenditures | -3.00K | — | -21.00K | — | — | -17.00K | -53.00K | -46.00K | — | -46.00K |
| Investing Cash Flow | 6.11M | -21.58M | -21.00K | — | — | -17.00K | 5.04M | -5.13M | 12.65M | 10.61M |
| Financing Cash Flow | 51.53M | 48.53M | 15.28M | 19.32M | 36.61M | 32.68M | 17.32M | 19.76M | 2.00M | 150.00K |
| Net Change in Cash | 8.18M | -2.82M | -9.22M | -18.25M | 7.17M | 19.19M | 7.15M | 4.01M | 5.54M | -52.00K |
| Free Cash Flow | -49.47M | -29.77M | -24.50M | -37.57M | -29.44M | -13.49M | -15.27M | -10.67M | -9.11M | -248.00K |
This table shows 10 annual periods of Achieve Life Sciences's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow QUIT's reporting calendar. What is a cash flow statement?